Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Go back to Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis| Enliven Marketing Technologies Corporation (NASDAQ: ENLV) | Delayed: 0.62 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.62 | 52 Week High | $0.94 | |||
| Open | $0.63 | 52 Week Low | $0.47 | |||
| Day High | $0.66 | P/E | N/A | |||
| Day Low | $0.59 | EPS | $-0.11 | |||
| Volume | 1,068,931 | |||||
